Inclusion and Reporting of Transgender and Nonbinary Persons in Clinical Trials and Tumor Registries-The Time Is Now.

IF 22.5 1区医学 Q1 ONCOLOGY JAMA Oncology Pub Date : 2022-06-09 DOI:10.1001/jamaoncol.2022.1638

C. Cortina

引用次数: 8

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

跨性别者和非二元性别者在临床试验和肿瘤登记中的纳入和报告——现在是时候了。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

JAMA Oncology Medicine-Oncology

自引率

1.80%

发文量

423

期刊介绍： JAMA Oncology is an international peer-reviewed journal that serves as the leading publication for scientists, clinicians, and trainees working in the field of oncology. It is part of the JAMA Network, a collection of peer-reviewed medical and specialty publications.

期刊最新文献

A Values Proposition for Cancer Care Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020 Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer Regulatory Fate of Cancer Indications in the European Union After Accelerated Approval in the US